L19TNF联合多柔比星在晚期肿瘤(含肉瘤)中的I期剂量递增与扩展研究
两项I期研究评估L19TNF联合多柔比星在实体瘤(尤其软组织肉瘤)中的安全性、推荐剂量及疗效。第一项研究纳入27例患者,剂量限制性毒性出现在17 μg/kg L19TNF或75 mg/m2多柔比星,推荐剂量为13 μg/kg L19TNF联合60 mg/m2多柔比星。扩展队列15例可评估软组织肉瘤患者中观察到抗肿瘤活性,中位总生存期为14.9个月。
要点
- 推荐剂量为L19TNF 13 μg/kg联合多柔比星60 mg/m2。
- 剂量限制性毒性发生于L19TNF 17 μg/kg或多柔比星75 mg/m2。
- 经重度治疗的软组织肉瘤患者中位总生存期14.9个月。
核心结论
- L19TNF可安全与多柔比星联用,并在软组织肉瘤患者中诱导令人鼓舞的肿瘤缓解。
研究设计与样本
- 第一项为开放标签、剂量递增和扩展I期研究,纳入27例患者,L19TNF在第1、3、5天静脉给药,多柔比星第1天给药,每3周重复。
- 扩展队列纳入软组织肉瘤患者;第二项研究尝试将多柔比星剂量重新递增至75 mg/m2联合L19TNF 13 μg/kg。
- 主要目标包括确定推荐剂量。
主要发现
- 联合方案可安全应用,剂量限制性毒性发生于17 μg/kg L19TNF或75 mg/m2多柔比星。
- 推荐剂量为13 μg/kg L19TNF联合60 mg/m2多柔比星。
- 扩展队列15例可评估疗效的软组织肉瘤患者中,完全缓解1例、部分缓解1例、轻微肿瘤缩小7例。
- 该经重度治疗队列的中位总生存期为14.9个月。
关键数值与推荐
- 推荐剂量:L19TNF 13 μg/kg联合多柔比星60 mg/m2。
- 剂量限制性毒性阈值:L19TNF 17 μg/kg或多柔比星75 mg/m2。
- 软组织肉瘤扩展队列可评估疗效者15例,完全缓解1例、部分缓解1例、轻微肿瘤缩小7例。
- 经重度治疗软组织肉瘤队列中位总生存期14.9个月。
临床怎么用
- 对于晚期软组织肉瘤,可考虑L19TNF 13 μg/kg联合多柔比星60 mg/m2的I期推荐剂量方案,但需在临床试验框架下使用。
- 治疗期间需监测剂量限制性毒性,避免L19TNF超过17 μg/kg或多柔比星超过75 mg/m2。
局限性
- 研究为I期设计,样本量有限,疗效数据主要来自小规模扩展队列。
- 软组织肉瘤疗效可评估患者仅15例,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: L19TNF is a recombinant fusion protein composed of a human antibody fragment and human tumour necrosis factor. L19TNF targets the EDB domain of oncofetal fibronectin highly expressed in tumour vasculature and induces tumour remission in mouse tumours. We summarise two phase I trials testing a combination of L19TNF with doxorubicin in patients with solid tumours, particularly soft tissue sarcomas (STS). PATIENTS AND METHODS: The first study, an open-label, dose-escalation and expansion phase I study of L19TNF plus doxorubicin, enrolled 27 patients. Three cohorts (10.4-17 μg/kg L19TNF) of patients received L19TNF intravenously at days 1, 3, and 5 and doxorubicin (75 mg/m2, then 60 mg/m2) on day 1 every 3 weeks. The expansion cohort enrolled patients with STS. The second study tried to re-escalate the doxorubicin dose to 75 mg/m2 with 13 μg/kg L19TNF. Among primary objectives was the establishment of a recommended dose (RD). RESULTS: The combination was safely applicable. Dose-limiting toxicity occurred either at 17 μg/kg L19TNF or at 75 mg/m2 doxorubicin. RD is 13 μg/kg L19TNF plus 60 mg/m2 doxorubicin. In 15 STS patients of the extension cohort evaluable for efficacy, antitumour activity was observed with complete remission in 1, partial remission in 1 and minor tumour shrinkage in 7 patients. The median overall survival for this heavily pretreated cohort was 14.9 months. CONCLUSION: L19TNF can be safely applied in combination with doxorubicin and induces encouraging tumour remissions in patients with soft tissue sarcomas.
引用
- Schliemann C, Hemmerle T, Berdel AF, et al. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. Eur J Cancer. 2021. PMID: 33901793. doi:10.1016/j.ejca.2021.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。